Tenderwize
Wróć do wyszukiwania

Non-exclusive agreements for medicinal products containing Roxadustat (ATC B03XA05) via an open-house model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline May 31, 2028 · 643 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Roxadustat (ATC-Code: B03XA05) im Wege eines Open-House-Modells

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

No guaranteed volumes; actual demand depends on patient numbers, prescribing behavior, and pharmacy stocking.

The agreement may be terminated early if the buyer concludes exclusive agreements, typically 8-12 months after publicat...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Non-exclusive supply of medicinal products containing Roxadustat (ATC B03XA05)
  • Open-house model allowing any qualified pharmaceutical company to participate
Pokaż pełne podsumowanie

This notice announces a non-exclusive open-house model agreement for pharmaceutical products containing Roxadustat (ATC B03XA05), organized by AOK PLUS for the regions of Saxony and Thuringia, Germany. The agreement has no guaranteed volumes, no exclusivity, and allows any qualified pharmaceutical company to join during the participation period. The procedure is not a public procurement under EU directives but a voluntary transparency measure. Submissions are accepted periodically until 31 May 2028, with the first deadline on 30 April 2026.

Ryzyka

No guaranteed volumes; actual demand depends on patient numbers, prescribing behavior, and pharmacy stocking.

The agreement may be terminated early if the buyer concludes exclusive agreements, typically 8-12 months after publicat...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company as defined in §4(18) AMG
  • Must have a registered office within the EU/EEA or Germany
  • Must accept the non-exclusive, no-negotiation open-house model

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No explicit award criteria in provided data; award is based on acceptance of terms and conditions.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive agreements for medicinal products containing Roxadustat (ATC B03XA05) via an open-house model

Non-exclusive framework agreement for the supply of Roxadustat (ATC B03XA05) under an open-house model. No minimum purchase quantities, no exclusivity, and individual negotiations are not conducted. The agreement ends no later than 31 May 2028.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

May 2026 - May 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

No explicit award criteria in provided data; award is based on acceptance of terms and conditions.

Termin

Deadline May 31, 2028

Szczegóły zamówienia

Data publikacji
29 Mar 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
216077-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3